Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinical Hold For Merck KGaA’s BTK Inhibitor Evobrutinib For MS Raises Class Safety Fears

Third To Be Hit With MS Clinical Hold

Executive Summary

Adding to a growing pattern within the BTK inhibitor pipeline for multiple sclerosis, the US FDA has placed Merck’s evobrutinib on a partial clinical hold following two liver injury incidents, prompting questions over its ultimate approvability.

You may also be interested in...

Novartis’s Remibrutinib Succeeds In Pivotal CSU Trials With Promise Of Liver Safety

The major’s BTK inhibitor candidate, remibrutinib, met the primary and secondary endpoints of two Phase III trials in chronic spontaneous urticaria, with unproblematic liver function results so far, suggesting it may avoid pitfalls faced by rivals.

All Eyes On Sanofi’s MS Efforts As Aubagio Plummets Upon Generic Entries

The French firm’s ex-blockbuster multiple sclerosis drug, Aubagio, saw sales more than halve as generics made their mark, prompting the firm to tout recent developments for two pipeline contenders for the disease.

Roche Eyes More Growth Opportunities For Vabysmo

The Swiss behemoth’s top five growth drivers – Vabysmo, Ocrevus, Hemlibra, Evrysdi and Phesgo – are selling well and softening the loss in earnings from products that boomed during COVID-19.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts